Last reviewed · How we verify
LAC triple therapy
LAC triple therapy is a Small molecule drug developed by National Cancer Center, Korea. It is currently in Phase 3 development for Cancer (specific indication not publicly detailed). Also known as: PPI-Clarithromycin containing triple therapy.
LAC triple therapy combines three agents to enhance anti-tumor immune response and inhibit cancer cell proliferation through complementary mechanisms.
Tegoprazan, in combination with amoxicillin and clarithromycin, is a triple therapy used to treat Helicobacter Pylori infection. This therapy is also being studied for its potential efficacy in gastric cancer, although the exact mechanism of action is a small molecule modality.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LAC triple therapy |
|---|---|
| Also known as | PPI-Clarithromycin containing triple therapy |
| Sponsor | National Cancer Center, Korea |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
LAC triple therapy typically refers to a combination regimen used in oncology that may include chemotherapy, targeted therapy, or immunotherapy components. The specific composition and mechanism depend on the cancer type being treated. As a phase 3 investigational regimen from the National Cancer Center Korea, it is designed to improve efficacy over standard treatments through synergistic effects of its component drugs.
Approved indications
- Cancer (specific indication not publicly detailed)
Common side effects
Key clinical trials
- Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication (PHASE3)
- Triple Therapy With Tegoprazan in H. Pylori Positive Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAC triple therapy CI brief — competitive landscape report
- LAC triple therapy updates RSS · CI watch RSS
- National Cancer Center, Korea portfolio CI
Frequently asked questions about LAC triple therapy
What is LAC triple therapy?
How does LAC triple therapy work?
What is LAC triple therapy used for?
Who makes LAC triple therapy?
Is LAC triple therapy also known as anything else?
What development phase is LAC triple therapy in?
Related
- Manufacturer: National Cancer Center, Korea — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cancer (specific indication not publicly detailed)
- Also known as: PPI-Clarithromycin containing triple therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing